Amorphous Enzalutamide Solid Dispersion for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of enzalutamide suffer from low solubility and absorption, leading to inadequate oral bioavailability and dissolution stability, which hampers effective treatment of castration-resistant prostate cancer and other conditions.
Innovation Solution
Development of amorphous enzalutamide solid dispersions combined with concentration-enhancing polymers, such as HPMCAS-MG and PVPVA, to enhance solubility and absorption, resulting in rapid disintegration and dispersibility, allowing for a single dosage unit to deliver the entire daily therapeutic dose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline enzalutamide is used in conventional formulations, then the formulation structure is simple and stable, but the solubility and oral bioavailability are insufficient
Solution Approach 1:
The patent transforms enzalutamide from crystalline state to amorphous state, fundamentally changing the physical state parameter to achieve superior solubility and oral bioavailability. The amorphous formulation provides at least 2-fold to 10-fold increases in maximum drug concentration and area under the curve compared to crystalline formulations.
Solution Approach 2:
The patent creates composite solid dispersion systems combining amorphous enzalutamide with concentration-enhancing polymers such as HPMCAS-MG and PVPVA. These composite materials leverage the synergistic effects of the amorphous drug and polymer matrix to achieve enhanced dissolution stability and bioavailability.
2Reliability
If amorphous enzalutamide solid dispersions with concentration-enhancing polymers are used, then solubility and absorption are significantly improved, but the formulation complexity increases
Solution Approach 1:
The patent introduces concentration-enhancing polymers (HPMCAS-MG, PVPVA) as intermediary substances that mediate between the amorphous enzalutamide and the aqueous environment. These polymers enhance solubility and stabilize the amorphous state, providing at least 2-fold to 10-fold increases in aqueous concentration through their concentration-enhancing properties.
3Reliability
If conventional crystalline formulations are used, then manufacturing is simpler, but dissolution stability is inadequate
Solution Approach 1:
The patent changes the physical state parameter from crystalline to amorphous, which fundamentally improves dissolution stability. The amorphous formulation provides rapid disintegration and dispersibility, ensuring consistent and reliable drug release profiles that overcome the dissolution instability of crystalline formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous enzalutamide formulations exhibit significantly improved aqueous concentration and oral bioavailability, achieving at least 2-fold to 10-fold increases in maximum drug concentration and area under the curve in in vitro and in vivo tests, enhancing treatment efficacy.
Implementation Method 1
amorphous enzalutamide solid dispersions
Implementation Method 2
concentration-enhancing polymers, such as HPMCAS-MG and PVPVA, to enhance solubility and absorption
Data Source
AI summary
This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.